Skip to main content

Advertisement

ADVERTISEMENT

Poster LR-015

Microporous Annealed Particle (MAP) Wound Matrix, a New Scaffold for Complex Wounds

Abstract Body: Background: Microporous Annealed Particle (MAP) technology is a ‘smart’ flowable and resorbable wound matrix with a unique porous microenvironment that enables rapid tissue integration without eliciting a foreign body response. The MAP Wound Matrix enables, with a single application, a new treatment for complex wounds of any shape without the use of cells, biologics or growth factors. Objective: The purpose of this study was to demonstrate I) the unique healing capability of the MAP Wound Matrix in a controlled porcine cutaneous wound healing model, and II) the robustness of MAP treatment for complex lower-limb wounds in companion animals in a veterinary translational study. Methods: I) Porcine full-thickness excisional wounds were created using a 12-mm biopsy punch on the dorsum and treated with either MAP Wound Matrix, Aquaphor, or Oasis SIS decellularized matrix. Wounds were followed over 35 days, clinically assessed for gross wound contraction and local irritation, while histologically evaluated for inflammation, new tissue formation, and vascularization. II) Complex and high-risk lower-limb wounds that are typically untreatable due to exposed bone, tendon, and fascia were treated with MAP Wound Matrix in 15 veterinary canine cases after cancer mass removals. Results: I) In the porcine study, MAP showed lower acute tissue inflammation against the material compared to both Aquaphor and Oasis, with no granulomas in MAP after 21 days. MAP also promoted earlier wound vascularization and larger vessel formation compared to Aquaphor. II) In complex canine wounds, MAP led to early granulation (< 7 days) with complete wound closure after 20-30 days creating a scar-free regenerated skin with new skin appendages such as hair follicles. Conclusion: The MAP Wound Matrix demonstrates a clear immune privileged host response and has demonstrated superior performance across multiple non-primate species both in granulation over complex surfaces and wound closure relative to current clinical products.

Sponsor

Sponsor name
Tempo Therapeutics inc

Advertisement

Advertisement

Advertisement